Multivariate analysis of LFS and OS
| Variable . | n . | Relative risk (95% CI) . | P . |
|---|---|---|---|
| LFS | |||
| Donor type | .114 | ||
| Matched sibling | 212 | 1.00 | |
| URD, well-matched | 249 | 1.10 (0.86-1.40) | |
| URD, partially-matched | 99 | 1.38 (1.02-1.87)* | |
| Prior MDS | |||
| No | 452 | 1.00 | |
| Yes | 108 | 1.42 (1.10-1.84) | .007 |
| Graft type | |||
| In first 3 mo after treatment | |||
| BM | 228 | 1.00 | |
| PBPC | 332 | 0.6 (0.39-0.91) | .016 |
| After 3 mo after treatment | |||
| BM | 174 | 1.00 | |
| PBPC | 272 | 0.96 (0.71-1.3) | .8 |
| Age and conditioning regimen | |||
| In first 3 mo after treatment | .072 | ||
| 20-50 y, myeloablative | 252 | 1.00 | |
| Less than 20 y, myeloablative | 84 | 0.78 (0.43-1.41) | |
| More than 50 y, myeloablative | 82 | 0.86 (0.46-1.59) | |
| 50 y or less, RIC | 34 | 0.85 (0.33-2.14) | |
| More than 0 y, RIC | 108 | 1.75 1.08-2.83)* | |
| After 3 mo after treatment | < .001 | ||
| 20-50 y, myeloablative | 204 | 1.00 | |
| Less than 20 y, myeloablative | 68 | 0.88 (0.57-1.36) | |
| More than 50 y, myeloablative | 69 | 1.7 (1.17-2.47)* | |
| 50 y or less, RIC | 29 | 1.22 (0.69-2.16) | |
| More than 0 y, RIC | 76 | 2.56 (1.78-3.69)* | |
| Acute GVHD (grade 2-4, time-dependent) | |||
| No | 288 | 1.00 | |
| Yes | 272 | 1.53 (1.23-1.9) | < .001 |
| Chronic GVHD (time-dependent) | |||
| No | 331 | 1.00 | |
| Yes | 229 | 1.11 (0.83-1.48) | .48 |
| OS | |||
| Donor type | .07 | ||
| Matched sibling | 216 | 1.00 | |
| URD, well-matched | 251 | 1.06 (0.83-1.37) | |
| URD, partially-matched | 101 | 1.42 (1.04-1.94)* | |
| Therapy-related leukemia | |||
| No | 487 | 1.00 | |
| Yes | 81 | 1.44 (1.07-1.95) | .017 |
| Donor-recipient sex match | |||
| Male-male | 207 | 1.00 | .029 |
| Male-female | 153 | 0.67 (0.5-0.89)* | |
| Female-male | 109 | 0.74 (0.55-1.01)* | |
| Female-female | 99 | 0.78 (0.56-1.06) | |
| Graft type | |||
| In first 3 mo after treatment | |||
| BM | 231 | 1.00 | |
| PBPC | 337 | 0.51 (0.31-0.83) | .006 |
| After 3 mo after treatment | |||
| BM | 187 | 1.00 | |
| PBPC | 300 | 0.94 (0.71-1.26) | .7 |
| Age and conditioning regimen | |||
| In first 3 mo after treatment | .5 | ||
| 20-50 y, myeloablative | 254 | 1.00 | |
| Less than 20 y, myeloablative | 85 | 0.68 (0.35-1.32) | |
| More than 50 y, myeloablative | 85 | 0.7 (0.34-1.44) | |
| 50 y or less, RIC | 35 | 0.61 (0.19-2.16) | |
| More than 50 y, RIC | 109 | 1.15 (0.63-2.11) | 5 |
| After 3 mo after treatment | < .001 | ||
| 20-50 y, myeloablative | 214 | 1.00 | |
| Less than 20 y, myeloablative | 73 | 0.88 (0.58-1.34) | |
| More than 50 y, myeloablative | 76 | 1.82 (1.27-2.6)* | |
| 50 y or less, RIC | 32 | 1.19 (0.68-2.07) | |
| More than 50 y, RIC | 92 | 2.88 (2.05-4.04)* | |
| Acute GVHD (grade 2-4, time-dependent) | |||
| No | 287 | 1.00 | |
| Yes | 275 | 1.78 (1.42-2.22) | < .001 |
| Chronic GVHD (time-dependent) | |||
| No | 327 | 1.00 | |
| Yes | 230 | 0.91 (0.69-1.20) | .5 |
| Variable . | n . | Relative risk (95% CI) . | P . |
|---|---|---|---|
| LFS | |||
| Donor type | .114 | ||
| Matched sibling | 212 | 1.00 | |
| URD, well-matched | 249 | 1.10 (0.86-1.40) | |
| URD, partially-matched | 99 | 1.38 (1.02-1.87)* | |
| Prior MDS | |||
| No | 452 | 1.00 | |
| Yes | 108 | 1.42 (1.10-1.84) | .007 |
| Graft type | |||
| In first 3 mo after treatment | |||
| BM | 228 | 1.00 | |
| PBPC | 332 | 0.6 (0.39-0.91) | .016 |
| After 3 mo after treatment | |||
| BM | 174 | 1.00 | |
| PBPC | 272 | 0.96 (0.71-1.3) | .8 |
| Age and conditioning regimen | |||
| In first 3 mo after treatment | .072 | ||
| 20-50 y, myeloablative | 252 | 1.00 | |
| Less than 20 y, myeloablative | 84 | 0.78 (0.43-1.41) | |
| More than 50 y, myeloablative | 82 | 0.86 (0.46-1.59) | |
| 50 y or less, RIC | 34 | 0.85 (0.33-2.14) | |
| More than 0 y, RIC | 108 | 1.75 1.08-2.83)* | |
| After 3 mo after treatment | < .001 | ||
| 20-50 y, myeloablative | 204 | 1.00 | |
| Less than 20 y, myeloablative | 68 | 0.88 (0.57-1.36) | |
| More than 50 y, myeloablative | 69 | 1.7 (1.17-2.47)* | |
| 50 y or less, RIC | 29 | 1.22 (0.69-2.16) | |
| More than 0 y, RIC | 76 | 2.56 (1.78-3.69)* | |
| Acute GVHD (grade 2-4, time-dependent) | |||
| No | 288 | 1.00 | |
| Yes | 272 | 1.53 (1.23-1.9) | < .001 |
| Chronic GVHD (time-dependent) | |||
| No | 331 | 1.00 | |
| Yes | 229 | 1.11 (0.83-1.48) | .48 |
| OS | |||
| Donor type | .07 | ||
| Matched sibling | 216 | 1.00 | |
| URD, well-matched | 251 | 1.06 (0.83-1.37) | |
| URD, partially-matched | 101 | 1.42 (1.04-1.94)* | |
| Therapy-related leukemia | |||
| No | 487 | 1.00 | |
| Yes | 81 | 1.44 (1.07-1.95) | .017 |
| Donor-recipient sex match | |||
| Male-male | 207 | 1.00 | .029 |
| Male-female | 153 | 0.67 (0.5-0.89)* | |
| Female-male | 109 | 0.74 (0.55-1.01)* | |
| Female-female | 99 | 0.78 (0.56-1.06) | |
| Graft type | |||
| In first 3 mo after treatment | |||
| BM | 231 | 1.00 | |
| PBPC | 337 | 0.51 (0.31-0.83) | .006 |
| After 3 mo after treatment | |||
| BM | 187 | 1.00 | |
| PBPC | 300 | 0.94 (0.71-1.26) | .7 |
| Age and conditioning regimen | |||
| In first 3 mo after treatment | .5 | ||
| 20-50 y, myeloablative | 254 | 1.00 | |
| Less than 20 y, myeloablative | 85 | 0.68 (0.35-1.32) | |
| More than 50 y, myeloablative | 85 | 0.7 (0.34-1.44) | |
| 50 y or less, RIC | 35 | 0.61 (0.19-2.16) | |
| More than 50 y, RIC | 109 | 1.15 (0.63-2.11) | 5 |
| After 3 mo after treatment | < .001 | ||
| 20-50 y, myeloablative | 214 | 1.00 | |
| Less than 20 y, myeloablative | 73 | 0.88 (0.58-1.34) | |
| More than 50 y, myeloablative | 76 | 1.82 (1.27-2.6)* | |
| 50 y or less, RIC | 32 | 1.19 (0.68-2.07) | |
| More than 50 y, RIC | 92 | 2.88 (2.05-4.04)* | |
| Acute GVHD (grade 2-4, time-dependent) | |||
| No | 287 | 1.00 | |
| Yes | 275 | 1.78 (1.42-2.22) | < .001 |
| Chronic GVHD (time-dependent) | |||
| No | 327 | 1.00 | |
| Yes | 230 | 0.91 (0.69-1.20) | .5 |
In each comparison group, P values reflect an overall significant difference between the groups. Because of interactions between age and conditioning regimen as well as nonproportional hazards over time, TRM was analyzed by time periods as shown.
BM indicates bone marrow.
Significantly different value from the reference group.